Open AccessN-Nitrosodimethylamine-Contaminated Valsartan and the Risk of Cancer
Author(s) -
Willy Gomm,
Christoph Röthlein,
Katrin Schüssel,
Gabriela Brückner,
H. Schröder,
Steffen Hess,
Roland Frötschl,
Karl Broich,
Britta Haenisch
Publication year - 2021
Publication title -
deutsches ärzteblatt international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.436
H-Index - 60
ISSN - 1866-0452
DOI - 10.3238/arztebl.m2021.0129
Subject(s) - medicine , valsartan , cancer , cohort , confounding , hazard ratio , confidence interval , environmental health , oncology , blood pressure
N-Nitrosodimethylamine (NDMA), classified as a probable human carcinogen, has been found as a contaminant in the antihypertensive drug valsartan. Potentially carcinogenic effects associated with the consumption of NDMAcontaminated valsartan have not yet been analyzed in large-scale cohort studies. We therefore carried out the study reported here to explore the association between NDMA-contaminated valsartan and the risk of cancer.